South Korean health tech company Neurophet has obtained certification from Singapore's Health Sciences Authority for its AI-enabled degenerative brain disease diagnosis assistant software.
Its flagship software, Neurophet Aqua, analyses brain MRI using AI to check for brain atrophy and white matter degeneration as seen in neurodegenerative diseases such as Alzheimer's disease and vascular...
Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, scored $73 million in a Series B funding round led by FoundersX Ventures, bringing its total raise to $93 million.
All existing investors participated in the round alongside new investors Starbloom Capital, Alzheimer's Drug Discovery Foundation, WS Investment Company and IAG Capital.
In...
Fujifilm Corporation has developed AI technology that can predict whether patients with mild cognitive impairment will progress to Alzheimer's disease within two years.
According to a press statement, the AI Technology for AD Progression Prediction has been found to have high generalisability, predicting patients who would progress to AD with high accuracy, even for subjects from different...
Those keeping an eye on the digital therapeutics industry over the last several years likely remember the name Dthera Sciences.
The startup and its CEO Ed Cox became one of the developing space's many standard bearers around 2018. During that timeframe it landed a Breakthrough Device designation from the FDA for its Alzheimer's symptoms treatment, with Cox chairing a handful of industry...
Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation therapy slowed declines in memory and cognition among mild-to-moderate Alzheimer's disease patients.
The OVERTURE study, a multi-center, randomized controlled trial, enrolled 76 such patients aged 50...
Biogen has announced a new multiyear research study on cognitive decline that will be conducted using the Apple Watch and iPhone.
The observational study is being conducted in collaboration with Apple, according to the announcement, and is set to kick off later this year. The project's primary goal is to establish digital biomarkers for monitoring long-term cognitive performance and to spot early...
Sensors from consumer-grade devices like iPhones, Apple Watches, iPads and Beddit sleep monitors capture enough data to spot mild cognitive impairment or Alzheimer’s disease dementia, according to a new feasibility study conducted jointly by Apple, Eli Lilly and Company and Evidation Health researchers that was presented today at a research conference held in Anchorage, Alaska.
“Over the past few...
This morning Altoida, a digital platform that uses artificial intelligence and machine learning to help predict Alzheimer’s disease, closed a $6.3 million Series A funding round. M Ventures led the round with participation from Grey Sky Venture Partners, VI Partners AGG, Alpana Ventures and FYRFLY Ventures.
WHAT THEY DO
Altoida makes a digital platform that employs AI, ML and augmented reality...
Optina Diagnostics, a Montreal-based company that uses spectral retinal imaging and artificial intelligence to scan for early Alzheimer’s disease, announced today that it has raised $4 million in seed funding. Zoic Capital led the round with participation from Desjardins Capital, DigitalDx Ventures, Pallasite Ventures, Barney Pell, Barney Pell's AngelList Syndicate, Advisors.fund and Hike...
Dthera Sciences, a San Diego-based developer of clinical and consumer digital therapeutics for individuals with neurodegenerative conditions, announced today that its development stage intervention, DTHR-ALZ, has been granted Breakthrough Device designation by the FDA.
As laid out in the 21st Century Cures Act, the Breakthrough Devices Program looks to streamline new medical technologies that...
